drugset / Trial / NCT01842594

A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma

NCT01842594

Phase 2 Terminated 13 enrolled Shin Kong Wu Ho-Su Memorial Hospital
NaSingle-groupOpen-labelTreatment

Summary

Determine the objective response rate in sarcoma patients treated with hydroxychloroquine and sirolimus.

Timeline

Start
2012-08
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 400 mg Oral
Subject Sirolimus Small molecule 2 mg Oral

Indications